USS Investment Management Ltd Cuts Holdings in Humana Inc. (NYSE:HUM)

USS Investment Management Ltd lessened its stake in Humana Inc. (NYSE:HUM - Free Report) by 9.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 20,056 shares of the insurance provider's stock after selling 2,061 shares during the quarter. USS Investment Management Ltd's holdings in Humana were worth $5,087,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the stock. FPC Investment Advisory Inc. purchased a new stake in Humana during the fourth quarter worth $27,000. Centricity Wealth Management LLC acquired a new position in Humana during the fourth quarter worth $30,000. LFA Lugano Financial Advisors SA grew its position in shares of Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock valued at $32,000 after purchasing an additional 45 shares during the period. OFI Invest Asset Management purchased a new stake in shares of Humana during the fourth quarter worth about $33,000. Finally, Transce3nd LLC purchased a new position in Humana in the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Trading Up 0.4%

Shares of NYSE HUM traded up $1.01 during trading on Tuesday, reaching $225.94. The stock had a trading volume of 968,259 shares, compared to its average volume of 1,777,620. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The company has a market cap of $27.27 billion, a P/E ratio of 22.71, a PEG ratio of 2.05 and a beta of 0.49. Humana Inc. has a fifty-two week low of $212.45 and a fifty-two week high of $406.46. The business's 50-day moving average price is $260.33 and its 200-day moving average price is $268.05.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to analyst estimates of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The business's revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $7.23 earnings per share. On average, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 dividend on an annualized basis and a yield of 1.57%. Humana's dividend payout ratio (DPR) is presently 25.04%.

Analyst Upgrades and Downgrades

A number of brokerages have commented on HUM. Oppenheimer increased their target price on Humana from $300.00 to $310.00 and gave the company an "outperform" rating in a report on Thursday, May 1st. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Wall Street Zen upgraded shares of Humana from a "hold" rating to a "buy" rating in a report on Friday, May 9th. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 18th. Finally, Mizuho upped their price target on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research report on Wednesday, April 9th. Seventeen analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Humana presently has an average rating of "Hold" and a consensus price target of $286.81.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.